Record-high first-half sales and profits were driven by strong cosmetics, private brand growth, and inbound demand, with cost controls offsetting inflation and drug price pressures. Full-year guidance is unchanged, and shareholder returns are increasing through higher dividends and buybacks.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.